Exhonit Therapeutics

Exhonit Therapeutics is a biotechnology company dedicated to developing transformative therapies for neurodegenerative disorders through the modulation of RNA splicing. The company specifically targets the Cdc2-like kinase (CLK) family using proprietary small molecule inhibitors to address the underlying pathology of diseases such as Amyotrophic Lateral Sclerosis (ALS). By correcting splicing errors, Exhonit aims to restore cellular function and prevent neuronal death. The company was founded on pioneering research from the Hebrew University of Jerusalem and operates within the FutuRx incubator ecosystem. Backed by prominent investors including Takeda Ventures and Johnson & Johnson Innovation, Exhonit is currently advancing its lead programs through the pre-clinical stage.